Close
4

Overview

Client Email Product
CAS 144689-63-4
PharmaCompass
CAS 144689-63-4
Also known as: 144689-63-4, Benicar, Olmetec, Cs-866, Cs 866, Olmesartan (medoxomil)
Molecular Formula
C29H30N6O6
Molecular Weight
558.595  g/mol
InChI Key
UQGKUQLKSCSZGY-UHFFFAOYSA-N
FDA UNII
6M97XTV3HD

An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.
1 2D Structure

CAS 144689-63-4

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
2.1.2 InChI
InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
2.1.3 InChI Key
UQGKUQLKSCSZGY-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
2.2 Other Identifiers
2.2.1 UNII
6M97XTV3HD
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 144689-63-4

2. Benicar

3. Olmetec

4. Cs-866

5. Cs 866

6. Olmesartan (medoxomil)

7. Benevas

8. Olvance

9. Unii-6m97xtv3hd

10. Benicar (tn)

11. Olmetec (tn)

12. Ks-1182

13. 6m97xtv3hd

14. Benicar Hct

15. Cs-866dm

16. Cs-866rn

17. C29h30n6o6

18. De-092

19. Ncgc00095136-01

20. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

21. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) Methyl Ester

22. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

23. Olsertain

24. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

25. (5-methyl-2-oxo-2h-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1h-imidazole-5-carboxylate

26. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

27. 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolecarboxylic Acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

28. Votume

29. Openvas

30. Olmesartanmedoxomil

31. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

32. Olmesartan Medoxomil [usan:inn:ban]

33. Spectrum_001944

34. Spectrum2_000506

35. Spectrum3_001676

36. Spectrum4_000740

37. Spectrum5_001556

38. D07ubg

39. Benicar, Olmetec,olmesartan

40. Dsstox_cid_25924

41. Dsstox_rid_81226

42. Dsstox_gsid_45924

43. Schembl16403

44. Bspbio_003491

45. Gtpl591

46. Kbiogr_001040

47. Kbioss_002498

48. Mls006010109

49. Bio-0071

50. Spectrum1505205

51. Spbio_000431

52. Olmesartan Medoxomil (benicar)

53. Ac1l2y71

54. Chembl1200692

55. Dtxsid9045924

56. Chebi:31932

57. Chebi:93384

58. Kbio2_002490

59. Kbio2_005058

60. Kbio2_007626

61. Kbio3_002711

62. Ks-00000ivq

63. Aob3863

64. Olmesartan Medoxomil (jan/usan)

65. Uqgkuqlkscszgy-uhfffaoysa-n

66. Cs866

67. Hms1922l15

68. Hms2089k18

69. Hms2093k16

70. Hms3651e13

71. Pharmakon1600-01505205

72. Ebd35964

73. Olmesartan Medoxomil (jp17/usan)

74. Zinc4149248

75. Tox21_111445

76. Bdbm50442892

77. Ccg-39596

78. Forest Brand Of Olmesartan Medoxomil

79. Mfcd00944911

80. Nsc758924

81. Olmesartan Medoxomil Tablets (jp17)

82. S1604

83. Sankyo Brand Of Olmesartan Medoxomil

84. Stl451024

85. Akos015894907

86. Akos015914772

87. Ac-1601

88. An-1125

89. Bcp9000555

90. Ccg-221184

91. Cs-0577

92. Mcule-2480015750

93. Nsc-758924

94. Olmesartan Medoxomil, >=98% (hplc)

95. Rp17784

96. Ncgc00095136-02

97. Ncgc00095136-03

98. (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate

99. Ak-72894

100. Bc208264

101. Bc209016

102. Br-72894

103. Cpd004727564

104. Dr003267

105. He311789

106. Hy-17005

107. Nu006784

108. Sam001246634

109. Sc-17112

110. Smr002203616

111. Sbi-0206741.p001

112. Ab0012006

113. Ab1009487

114. Berlin-chemie Brand Of Olmesartan Medoxomil

115. Ls-181818

116. Cas-144689-63-4

117. Ft-0601603

118. O0510

119. St24031498

120. D01204

121. J10058

122. S-1787

123. Ab01275443-01

124. Ab01275443_02

125. Ab01275443_03

126. 689o634

127. A808260

128. L001061

129. Sr-05000001987

130. I06-0025

131. J-501595

132. Sr-05000001987-2

133. Brd-k78485176-001-02-9

134. I14-41691

135. Z1550675457

136. Olmesartan Medoxomil, European Pharmacopoeia (ep) Reference Standard

137. Olmesartan Medoxomil, United States Pharmacopeia (usp) Reference Standard

138. Olmesartan Medoxomil For System Suitability, European Pharmacopoeia (ep) Reference Standard

139. Olmesartan Medoxomil, Pharmaceutical Secondary Standard; Certified Reference Material

140. (5-methyl-2-oxidanylidene-1,3-dioxol-4-yl)methyl 5-(2-oxidanylpropan-2-yl)-2-propyl-3-[[4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

141. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-h

142. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-i Midazole-5-carboxylate

143. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

144. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

145. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

146. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-[[2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-4-(2-hydroxypr

147. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxy-2-propanyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)-4-biphenylyl]methyl]-1h-imidazole-5-carboxylate

148. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylate

149. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(1-hydroxy-1-methyl-ethyl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

150. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-({4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)imidazole-4-carboxylate

151. (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate

152. (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate

153. (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenylmethyl}imidazol-5-carboxylate;

154. (5-methyl-2-oxo-1,3-dioxolen-4yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate

155. (5-methyl-2-oxo-2h-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-imidazole-5-carboxylate

156. 5-(1-hydroxy-1-methyl-ethyl)-2-propyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazole-4-carboxylic Acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl Ester

157. 5-(1-hydroxy-1-methylethyl)-2-propyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazole-4-carboxylic Acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl Ester

158. Olmesartan Medoxomil

159. 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic Acid-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

160. Olmetec; 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1htetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic Acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 558.595 g/mol
Molecular Formula C29H30N6O6
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count10
Rotatable Bond Count11
Exact Mass558.223 g/mol
Monoisotopic Mass558.223 g/mol
Topological Polar Surface Area154 A^2
Heavy Atom Count41
Formal Charge0
Complexity969
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 8  
Drug NameOLMESARTAN MEDOXOMIL
Active IngredientOLMESARTAN MEDOXOMIL
CompanyACCORD HLTHCARE (Application Number: A207662); ALEMBIC PHARMS LTD (Application Number: A203012); ALKEM LABS LTD (Application Number: A206763); AUROBINDO PHARMA LTD (Application Number: A204798); GLENMARK PHARMS LTD (Application Number: A203281); JUBILANT GENERICS (Application Number: A205482); LUPIN LTD (Application Number: A206631); MACLEODS PHARMS LTD (Application Number: A204814); MYLAN PHARMS INC (Application Number: A078276); TEVA PHARMS USA (Application Number: A091079); TORRENT PHARMS LTD (Application Number: A202375); ZYDUS PHARMS USA INC (Application Number: A205192)

2 of 8  
Drug NameAZOR
Active IngredientAMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL
CompanyDAIICHI SANKYO (Application Number: N022100)

3 of 8  
Drug NameBENICAR HCT
Active IngredientHYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
CompanyDAIICHI SANKYO (Application Number: N021532)

4 of 8  
Drug NameTRIBENZOR
Active IngredientAMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
CompanyDAIICHI SANKYO (Application Number: N200175)

5 of 8  
Drug NameBENICAR
Active IngredientOLMESARTAN MEDOXOMIL
CompanyDAIICHI SANKYO (Application Number: N021286)

6 of 8  
Drug NameAMLODIPINE AND OLMESARTAN MEDOXOMIL
Active IngredientAMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL
CompanyAJANTA PHARMA LTD (Application Number: A207216); ALEMBIC PHARMS LTD (Application Number: A207073); ALKEM LABS LTD (Application Number: A209042); AUROBINDO PHARMA LTD (Application Number: A206906); GLENMARK PHARMS LTD (Application Number: A207807); JUBILANT GENERICS (Application Number: A207450); MACLEODS PHARMS LTD (Application Number: A206884); MICRO LABS (Application Number: A207435); TEVA PHARMS USA (Application Number: A091154); TORRENT PHARMS LTD (Application Number: A202933); ZYDUS PHARMS USA INC (Application Number: A207771)

7 of 8  
Drug NameOLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Active IngredientHYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
CompanyALEMBIC PHARMS LTD (Application Number: A204233); AUROBINDO PHARMA LTD (Application Number: A205391); MYLAN PHARMS INC (Application Number: A078827); PRINSTON INC (Application Number: A207804); TEVA PHARMS USA (Application Number: A200532); TORRENT PHARMS LTD (Application Number: A206515)

8 of 8  
Drug NameOLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
Active IngredientAMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
CompanyPAR PHARM INC (Application Number: A206137); TEVA PHARMS USA (Application Number: A202491); TORRENT PHARMS LTD (Application Number: A203580)

5 Pharmacology and Biochemistry
5.1 Pharmacology

Olmesartan Medoxomil is a synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor of angiotensin II in vascular smooth muscle and adrenal gland, thereby competing angiotensin II binding to the receptor. This prevents angiotensin II-induced vasoconstriction and decreases aldosterone production, thereby preventing aldosterone-stimulated sodium retention and potassium excretion.


5.2 MeSH Pharmacological Classification

Angiotensin II Type 1 Receptor Blockers

Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.


Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.


5.3 ATC Code

C - Cardiovascular system
C09 - Agents acting on the renin-angiotensin system
C09C - Angiotensin ii antagonists, plain
C09CA - Angiotensin ii antagonists, plain
C09CA08 - Olmesartan medoxomil


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty

Advertise With Us

Advertise With Us